Monopar Therapeutics Net Income

The latest net income for MNPR is $-3.5B as of June 2026. That compares with $-3.9B in the prior-year period — up 12.4% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Monopar Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MNPR's net income moved from $-3.9B to $-3.5B — a 12.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Monopar Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, MNPR currently prints $-3.5B for net income, while the sector average sits near $16B. That is roughly 121.0% below the sector mean. Large gaps often invite a closer look at Monopar Therapeutics's growth, margins, and balance sheet.

A net income figure of $-3.5B for MNPR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting MNPR's net income ($-3.5B), review year-over-year change from $-3.9B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.